King's College London

Research portal

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

Research output: Contribution to journalArticle

Standard

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. / Ashton, Nicholas J.; Suárez-Calvet, Marc; Heslegrave, Amanda; Hye, Abdul; Razquin, Cristina; Pastor, Pau; Sanchez-Valle, Raquel; Molinuevo, José L.; Visser, Pieter Jelle; Blennow, Kaj; Hodges, Angela; Zetterberg, Henrik.

In: Alzheimer's research & therapy, Vol. 11, No. 1, 94, 28.11.2019.

Research output: Contribution to journalArticle

Harvard

Ashton, NJ, Suárez-Calvet, M, Heslegrave, A, Hye, A, Razquin, C, Pastor, P, Sanchez-Valle, R, Molinuevo, JL, Visser, PJ, Blennow, K, Hodges, A & Zetterberg, H 2019, 'Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers', Alzheimer's research & therapy, vol. 11, no. 1, 94. https://doi.org/10.1186/s13195-019-0545-5

APA

Ashton, N. J., Suárez-Calvet, M., Heslegrave, A., Hye, A., Razquin, C., Pastor, P., ... Zetterberg, H. (2019). Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's research & therapy, 11(1), [94]. https://doi.org/10.1186/s13195-019-0545-5

Vancouver

Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P et al. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's research & therapy. 2019 Nov 28;11(1). 94. https://doi.org/10.1186/s13195-019-0545-5

Author

Ashton, Nicholas J. ; Suárez-Calvet, Marc ; Heslegrave, Amanda ; Hye, Abdul ; Razquin, Cristina ; Pastor, Pau ; Sanchez-Valle, Raquel ; Molinuevo, José L. ; Visser, Pieter Jelle ; Blennow, Kaj ; Hodges, Angela ; Zetterberg, Henrik. / Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. In: Alzheimer's research & therapy. 2019 ; Vol. 11, No. 1.

Bibtex Download

@article{6d707c648b594dd9a9eee3803869944d,
title = "Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers",
abstract = "BackgroundResults from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia.MethodsIn this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers.ResultsOur results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD.ConclusionConcentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.",
keywords = "Alzheimer's disease, Biomarkers, Blood, Neurofilament light chain, sTREM2",
author = "Ashton, {Nicholas J.} and Marc Su{\'a}rez-Calvet and Amanda Heslegrave and Abdul Hye and Cristina Razquin and Pau Pastor and Raquel Sanchez-Valle and Molinuevo, {Jos{\'e} L.} and Visser, {Pieter Jelle} and Kaj Blennow and Angela Hodges and Henrik Zetterberg",
year = "2019",
month = "11",
day = "28",
doi = "10.1186/s13195-019-0545-5",
language = "English",
volume = "11",
journal = "Alzheimer's research & therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

AU - Ashton, Nicholas J.

AU - Suárez-Calvet, Marc

AU - Heslegrave, Amanda

AU - Hye, Abdul

AU - Razquin, Cristina

AU - Pastor, Pau

AU - Sanchez-Valle, Raquel

AU - Molinuevo, José L.

AU - Visser, Pieter Jelle

AU - Blennow, Kaj

AU - Hodges, Angela

AU - Zetterberg, Henrik

PY - 2019/11/28

Y1 - 2019/11/28

N2 - BackgroundResults from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia.MethodsIn this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers.ResultsOur results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD.ConclusionConcentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.

AB - BackgroundResults from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia.MethodsIn this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers.ResultsOur results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD.ConclusionConcentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.

KW - Alzheimer's disease

KW - Biomarkers

KW - Blood

KW - Neurofilament light chain

KW - sTREM2

UR - http://www.scopus.com/inward/record.url?scp=85075786544&partnerID=8YFLogxK

U2 - 10.1186/s13195-019-0545-5

DO - 10.1186/s13195-019-0545-5

M3 - Article

VL - 11

JO - Alzheimer's research & therapy

JF - Alzheimer's research & therapy

SN - 1758-9193

IS - 1

M1 - 94

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454